NKTX

NASD Nkarta, Inc.
Oct 19, 2026 · 10:47 PM ET EOD Market Closed

$1.75 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.75, $0.10 below the day’s high of $1.85

YTD change
-5.41%
vs 20-day SMA
-28.34%
vs 200-day SMA
-31.34%

Price ranges

Previous day
$1.78 $1.94
open $1.93 close $1.80
-$0.13 (-6.74%)
Today
$1.75 $1.85
open $1.84 now $1.75
-$0.09 (-4.89%)
Past week
$1.78 $2.28
from $2.25 now $1.75
-$0.50 (-22.22%)
Past month
$1.78 $2.99
from $2.83 now $1.75
-$1.08 (-38.16%)
This year
$1.75 $3.72
from $1.85 now $1.75
-$0.10 (-5.41%)

Price & Performance

-1.74 (-49.86%) / 6M

$1.60$2.34$3.08$3.82Apr 20Jul 21Oct 19

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 97.8% away from all-time highs of $79.16
  • NKTX is down 5% since the beginning of the year
  • NKTX is down 24% over the past 12 months
  • NKTX is down 38% over the past 1 month
  • 5% of all NKTX investors are betting against NKTX

NKTX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -28.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.54
Earnings momentum -36.7% Quarterly EPS growth
Quarterly change -36.7%

Valuation

P/E ratio N/A
Enterprise value $24.9M
Beta 2.94

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$182.8M
Debt$73.5K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $130.0M

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $424.94 -1.75%
MRNA Moderna, Inc. $226.89 +4.07%
RVMD Revolution Medicines, Inc. $182.15 +2.35%
ROIV Roivant Sciences Ltd. $34.70 +3.49%
BNTX BioNTech SE Sponsored ADR $89.21 +1.71%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.